Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB039110 or placebo plus docetaxel in previously treated advanced non-small cell lung cancer
2013-004812-24Phase 2Terminated
- Sponsor
- Incyte
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing INCB039110 + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Safety run-in (Part 1). Started Aug 2014; status: terminated.
02
Drugs
itacitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-004812-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004812-24.